The overall Objective of Biospecimens Accessioning and Processing Shared Resource (BAP) is to provide a central facility to electronically accession and process biospecimens intended for research by Cancer Center members.
The Specific Aims of the Shared Resource are to 1) provide electronic accessioning of biospecimens into a central Research Specimen Database, 2) to process the specimens appropriately according to their projected end use, 3) to provide nucleic acid extraction services, 4) to provide cryopreservation of mononuclear cells and EBV immortalization of B lymphocytes, and 5) to provide consultative services and specific expertise to Cancer Center investigators. Biospecimens accessioned through this resource include solid tissues as well as whole blood and other body fluids. Blood specimens are processed for nucleic acid extraction, future or immediate EBV immortalization of mononuclear cells, and/or frozen storage as plasma, serum or buffy coats. Fresh solid tissues are dissected and frozen in liquid nitrogen or freezing medium. One of the most valuable contributions of the BAP resource is the specimen annotation that is entered into the Research Laboratory Information System at the time of specimen accessioning and subsequently utilized for timely and appropriate retrieval of archived specimens. During the current funding period, BAP has developed substantial automation which has increased sample capacity without increased cost to investigators. Together, the electronic biospecimen accessioning combined with basic specimen processing, EBV immortalization, and nucleic acid extraction services have created a powerful, synergistic Shared Resource critical for support of translations!, epidemiologic and basic research of Cancer Center members. In 2007, the BAP Shared Resource processed over 1,700 cryopreservations and EBV transformations and extracted DNA from over 10,000 biospecimens for over 30 Cancer Center investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465657
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$159,544
Indirect Cost
$49,096
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Kenkre, Vaishalee P; Hong, Fangxin; Cerhan, James R et al. (2016) Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. Clin Cancer Res 22:821-6
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9

Showing the most recent 10 out of 948 publications